Principal Investigator
Cynthia Levy
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20241324
Clinical Trial Summary
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Erythropoietic protoporphyria (EPP)
Contact Information
Study Contact
Sonia Carvalho
Phone Number
+1 (305) 2434639
Email
scarvalho@miami.edu